

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

1042825

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International BureauLITERATUUR
OMPI

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/70	A1	(11) International Publication Number: WO 99/59601 (43) International Publication Date: 25 November 1999 (25.11.99)
<p>(21) International Application Number: PCT/NL99/00316</p> <p>(22) International Filing Date: 20 May 1999 (20.05.99)</p> <p>(30) Priority Data: 1009226 20 May 1998 (20.05.98) NL</p> <p>(71) Applicant (for all designated States except US): FACULTEIT GENEESKUNDE UNIVERSITEIT UTRECHT [NL/NL]; Universiteitsweg 100, NL-3508 TA Utrecht (NL).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): VAN ASBECK, Bernt, Sweder [NL/NL]; Verheullaan 19, NL-3971 RD Driebergen (NL). MARX, Johannes, Josephus, Maria [NL/NL]; Johan Buziaulaan 41, NL-3584 ZT Utrecht (NL).</p> <p>(74) Agent: ALTENBURG, Bernardus, Stephanus, Franciscus; Octrooibureau Los en Stigter B.V., Weteringschans 96, NL-1017 XS Amsterdam (NL).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p><i>In English translation (filed in Dutch).</i></p>
<p>(54) Title: USE OF A NUCLEIC ACID-BINDING CHEMOTHERAPEUTIC AGENT, AND A PHARMACEUTICAL COMPOSITION</p> <p>(57) Abstract</p> <p>The invention relates to the use of a nucleic acid-binding chemotherapeutic agent, such as bleomycin, wherein the nucleic acid-binding chemotherapeutic agent is capable of complexing a metal ion yielding a complex that promotes the formation of hydroxyl radicals from hydrogen peroxide. According to the present invention the agent is used for the preparation of a virion number-reducing agent. The invention also relates to a pharmaceutical composition.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Use of a nucleic acid-binding chemotherapeutic agent, and a pharmaceutical composition

The present invention relates to a use of a nucleic acid-binding chemotherapeutic agent, wherein the nucleic acid-binding chemotherapeutic agent is capable of complexing a metal ion, yielding a complex that promotes the formation of hydroxyl radicals from hydrogen peroxide.

Such a nucleic acid-binding chemotherapeutic agent is already known in the art. For example, certain neoplastic tissues (tumours) may be treated with bleomycin. Bleomycin is capable of binding bivalent iron, while the ferro-ion retains its ability to promote the formation of hydroxyl radicals from hydrogen peroxide.

It is the object of the present invention to provide a novel use of a nucleic acid-binding chemotherapeutic agent such as defined above.

According to the present invention the nucleic acid-binding chemotherapeutic agent can be used for the preparation of a virion number-reducing composition.

Surprisingly it has been found that by applying the above-defined nucleic acid-binding chemotherapeutic agent, the virus replication may be inhibited, without visible detriment to the host cell. Without being bound to any theory, applicant believes that the inhibition is specific because the formation of hydroxyl radicals from hydrogen peroxide is promoted especially in virus-infected cells.

According to a preferred embodiment, the nucleic acid-binding chemotherapeutic agent is selected from the group comprising bleomycin, adriamycin, and their derivatives.

These compounds possess excellent metal ion-complexing properties. In particular, they are capable of binding ferro-ions in the body of a patient. This enables the ferrobleomycin complex that is formed to promote the formation of hydroxyl radicals from hydrogen peroxide.

Preferably the nucleic acid-binding chemotherapeutic agent is used for the preparation of an RNA virus

replication-inhibiting agent, in particular the nucleic acid-binding chemotherapeutic agent is used for the preparation of a HIV replication-inhibiting agent.

Carter, B.J. et al. (Proc. Natl. Acad. Sci. USA, volume 87, pp. 9373-9377 (1990)) describe the effect of Fe(II)-bleomycin complex on mRNA which codes for reverse transcriptase of HIV-1. The experiment described was performed in a cell-free system. There is no indication that the formation of hydroxyl radicals from hydrogen peroxide is promoted preferentially in infected cells.

The invention further relates to a pharmaceutical combination composition comprising a nucleic acid-binding chemotherapeutic agent comprising a metal ion complexed therewith, which complex is able to promote the formation of hydroxyl radicals from hydrogen peroxide, together with a pharmaceutically acceptable carrier or excipient, and which also comprises an iron-chelating compound which binds iron in a form in which it is unable to promote the formation of hydroxyl radicals from hydrogen peroxide.

Such an iron-chelator combination which optionally comprises two separate pharmaceutical compositions, each of which possessing one of the respective active components, facilitates more specific localization of the formation of the hydroxyl radicals. By using an iron-chelating compound that is unable to penetrate the cells, it is possible to preferentially prevent the formation of ferro-bleomycin complex outside the cells, and consequently also to reduce the damage that such a complex causes. At the same time, the use of an iron-chelating compound that is able to penetrate the cells, will limit the amount of ferro-ions that limit the formation of hydroxyl radicals. In this way at least part of the activation process of the transcription factor Nuclear Factor kappa B (NF κ B), that can stimulate virus replication may be limited in the cytoplasm. However, it is necessary to ensure that iron is available for bleomycin. A physician may achieve this by choosing suitable doses of both active components, depending on the body weight of the person to be treated, and the person's available iron level. According to a favour-

able embodiment an iron-chelating compound is chosen having an iron-chelating capacity which is preferably at least three times lower, more preferably at least ten times lower than that of the nucleic acid-binding
5 chemotherapeutic agent.

Due to the greater affinity of bleomycin for iron, it is thus possible to promote the presence of active ferrobleomycin complex in infected cells and, in particular, to limit the extracellular detrimental effects of
10 bleomycin complex.

Applicant considers the possibility that the use of an iron-chelating compound as defined above may also be applied to limit undesired damage occurring during the treatment of neoplastic tissues with a nucleic acid-binding chemotherapeutic agent such as bleomycin.
15

The present invention will now be exemplified by way of example and with reference to the drawing in which

Fig. 1 shows a graph representing the effect of bleomycin on the HIV-1 replication in macrophages;

20 Fig. 2 shows a graph representing the site of toxicity of bleomycin for macrophages;

Fig. 3 shows a graph representing the effect of bleomycin on the HIV-1 replication in lymphocytes;

Fig. 4 shows a graph representing the effect of the
25 bleomycin concentration on the lymphocyte proliferation.

Example

Macrophages and lymphocytes (10^6 cells/ml) were infected with HIV-1_{Ba-L} for two hours. The ratio HIV particles/number of cells was 0.005 for macrophages and 0.001
30 for lymphocytes. The infected cells were then washed twice in order to remove excess virus. The cells were incubated for five days in RPMI 1640 medium (supplemented with 10% foetal calf serum, 10 U/ml of IL-2, 10 μ g/ml of gentamycin, and 0.5 μ g/ml of ciprofloxamine) with 3 iron chelators, being Deferoxamine (DI; Novartis Pharma, Arnhem, the Netherlands), Deferiprone (L1; Duchefa Farma B.V., Haarlem, the Netherlands) or Bleomycin (BLM; H. Lundbeck A/S, Copenhagen, Denmark). Virus in culture supernatant
35

was inactivated with Empigen (Calbiochem-Novabiochem Co., La Jolla, California, United States of America) in a final concentration of 0.05% and subsequently heated for 30 minutes at 56°C. The p24 concentration was determined in an ELISA, as measure for the replication of HIV-1 (Moore, J.P. et al., Science 250, pp. 1139-1142 (1990)). Cytotoxicity measurements were carried out using a fluorescence-activated cell sorter with the aid of colouring with propidium iodide and DiOC5 (3,3'-diapentiloxacarboxyl amine iodide). The proliferation of lymphocytes was measured by incorporation of ³H-thymidine. Figure 1 and Figure 2 show the dose-dependent reduction of the HIV-1 replication. The limited cytotoxicity of bleomycin for macrophages is appears from Figure 3. The insignificant effect of bleomycin on the proliferation of lymphocytes is shown in Figure 4. In contrast with DF and L1 which do inhibit cell proliferation (results not shown; L1 inhibits the proliferation substantially completely at 10 µM), the cell proliferation with bleomycin remains intact over a wide concentration range; this fact indicates that another mechanism which is not based on the inhibition of proliferation, is involved. Likewise, the BLM-induced reduction of HIV replication is not a result of cytotoxic effects of BLM.

In an attempt to find out more about the level at which the nucleic acid-binding chemotherapeutic agent is activated to reduce the number of virions in an infected cell, the transcription factors present on HIV-LTR (HIV-Long Terminal Repeat) have been studied, of which NFκB plays an important role in viral transcription. For the initiation of the transcription of pro-viral DNA present in the host genome, it is necessary that NFκB is present. EMSE analysis (Electrophoretic Mobility Shift Assay) of NFκB in nuclear extracts showed that bleomycin has no effect on NFκB activation, suggesting that HIV inhibition due to bleomycin occurs along a path other than transcription inhibition. The fact that NFκB prepared from nuclear extract prepared from Jurkat cells stimulated with 20 ng/ml phorbol myristate acetate (PMA) were not inhibited by BLM (concentrations up to 3 µg/ml), suggests that the

inhibition of HIV-1 by BLM occurs in another manner than that proposed for conventional iron chelators such as DF (Sappey et al. *Aids Res. Hum. Retroviruses* 11, pp 1049-1061 (1995)).

5 In order to see whether bleomycin is active at an earlier stage, i.e. before integration into the genome, the viral DNA-damaging properties of BLM in peripheral blood lymphocytes (PBL) infected with HIV-1 were examined. To this end the products of reverse transcription, among
10 which was the first minus strand strong stop DNA, were amplified using the R/U5 primers: sense 5'-GGCTAACTAGGGAA-CCCACTG-3' and antisense 5'-CTGCTAGAGATTTTCCACACTGAC-3' (biotinylated at 5' end), which resulted in a fragment of 140 bp. To quantify this fragment, a digoxigenin-labelled
15 probe 5'-TGTGTGCCCCGTCTGTTGTGTG-3' was used. Quantification was carried out with the aid of a DIG detection ELISA (Boehringer-Mannheim, Mannheim, Germany). After incubation with BLM, strong stop DNA which was formed in peripheral blood lymphocytes (PBL) infected with HIV, was virtually
20 absent. This could either mean that the reverse transcriptase enzyme is inhibited, or that the DNA products of reverse transcriptase are damaged by BLM directly.

Based on experiments that have been carried out, it is believed that bleomycin damages viral DNA and/or RNA in
25 the cytoplasm. The GAPDH-DNA concentration in the cell measured as control (GAPDH stands for glyceraldehyde-3-phosphate dehydrogenase) remains substantially constant, supporting the idea that the host DNA is fairly well protected against BLM, and that BLM preferably attacks
30 DNA/RNA in the cytosol, in this case viral DNA/RNA. This could also explain why in the first experiment described above, the p24 values, after incubation of the cells with BLM, were not reduced completely. After all, as the cells are incubated in the absence of BLM for 2 hours, some pro-
35 viral integration into the host genome will undoubtedly have occurred.

CLAIMS

1. A use of a nucleic acid-binding chemotherapeutic agent for the preparation of a viron number-reducing composition, wherein the nucleic acid-binding chemotherapeutic agent is capable of complexing a metal ion, yielding a
5 complex that promotes the formation of hydroxyl radicals from hydrogen peroxide.

2. A use according to claim 1, characterized in that the nucleic acid-binding chemotherapeutic agent is selected from the group comprising bleomycin, adriamycin,
10 and their derivatives.

3. A use according to claim 1 or 2, characterized in that the nucleic acid-binding chemotherapeutic agent is used for the preparation of an RNA virus number-reducing composition.

15 4. A use according to claim 3, characterized in that the nucleic acid-binding chemotherapeutic agent is used for the preparation of a HIV replication-inhibiting composition.

5. A pharmaceutical combination composition comprising a nucleic acid-binding chemotherapeutic agent comprising a metal ion complexed therewith, which complex is able to promote the formation of hydroxyl radicals from
20 hydrogen peroxide, together with a pharmaceutically acceptable carrier or excipient, and which also comprises an iron-chelating compound which binds iron in a form in
25 which it is unable to promote the formation of hydroxyl radicals from hydrogen peroxide.

6. A pharmaceutical combination composition according to claim 5, characterized in that iron-chelating compound has an iron-chelating capacity which is preferably
30 at least three times lower, more preferably at least ten times lower than that of the nucleic acid-binding chemotherapeutic agent.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 99/00316

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 138 480 A (GOSALVEZ) 6 February 1979 (1979-02-06) claims	5
A	E.A. SAUSVILLE ET AL.: "A role for ferrous ion and oxygen in the degradation of DNA by bleomycin." BIOCHEM. BIOPHYS. RES. COMMUN., vol. 73, no. 3, 1976, pages 814-822, XP002095484	
A	S. CHAKRABARTI ET AL.: "Measurement of hydroxyl radicals catalyzed in the immediate vicinity of DNA by metal-bleomycin complexes." FREE RADICAL BIOL. MED., vol. 20, no. 6, 1996, pages 777-783, XP002095485	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

12 October 1999

Date of mailing of the international search report

19/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Klaver, T

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 99/00316

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J.R.F. MUINDI ET AL.: "Hydroxyl radical production and DNA damage induced by anthracycline-iron complex." FEBS LETTERS, vol. 172, no. 2, 1984, pages 226-230, XP002095486	
A	R.M. BURGER ET AL.: "Mechanism of bleomycin action: in vitro studies." LIFE SCI., vol. 28, no. 7, 1981, pages 715-728, XP002095487	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NL 99/00316

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4138480 A	06-02-1979	ES 444380 A	16-06-1977
		AR 218620 A	30-06-1980
		AT 349634 B	10-04-1979
		AT 19677 A	15-09-1978
		AU 513698 B	18-12-1980
		BE 850438 A	16-05-1977
		CA 1070680 A	29-01-1980
		CH 629219 A	15-04-1982
		DD 129452 A	18-01-1978
		DE 2701405 A	21-07-1977
		DK 11877 A	17-07-1977
		EG 12735 A	31-03-1981
		FI 770115 A	17-07-1977
		FR 2338285 A	12-08-1977
		GB 1568263 A	29-05-1980
		GR 70696 A	30-12-1982
		IE 44689 B	24-02-1982
		JP 1364902 C	09-02-1987
		JP 52111555 A	19-09-1977
		JP 61033039 B	31-07-1986
		NL 7700379 A	19-07-1977
		NZ 183084 A	28-04-1980
		PH 16582 A	22-11-1983
		PT 66067 A, B	01-02-1977
		SE 7700398 A	17-07-1977
		SU 886748 A	30-11-1981
		YU 5477 A	30-06-1982

THIS PAGE BLANK (USPTO)